Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell”

StockNews.com downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other research firms have also recently weighed in on MCRB. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB opened at $0.82 on Friday. The business’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $0.91. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The firm has a market cap of $140.53 million, a price-to-earnings ratio of -3.58 and a beta of 2.13.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC increased its holdings in Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares in the last quarter. State Street Corp grew its holdings in shares of Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares in the last quarter. Providence Wealth Advisors LLC lifted its stake in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares in the last quarter. Finally, FMR LLC lifted its stake in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after acquiring an additional 140,096 shares in the last quarter. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.